Navigation Links
Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that Adrian Adams has been elected to the company's Board of Directors effective immediately.

"We are very pleased to welcome Adrian to the Amylin Board," said Daniel M. Bradbury, President and CEO of Amylin Pharmaceuticals. "His international experience as a highly innovative, strategic business leader, combined with a track record of building organizations and delivering optimum results will enhance our Board's depth of experience."

Mr. Adams currently serves as President and CEO of Sepracor, Inc. Prior to this he was President and Chief Executive Officer of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of experience in both specialty and large pharmaceutical organizations that, in addition to Sepracor and Kos, included careers with ICI, SmithKline Beecham and Novartis, and involved work and product launches in most therapeutic areas. Mr. Adams has a broad background encompassing research and development, sales, international and national product marketing, business development and extensive general management experience.

He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree.

In addition to serving on the Amylin Board, Mr. Adams is actively involved as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America).

About Amylin

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Group promoting classified research elects officers
4. Miller Brewing selects Procuri software
5. Uniden selects Catalyst RFID software
6. Hammes Co. selects SiteStuff as procurement company
7. Meat-snack maker selects Prescient Applied Intelligence tech package
8. UW Colleges selects Allot Communications to manage multi-campus network
9. ProHealth Care selects NetScaler delivery system
10. Merkle selects Firstlogic data quality software
11. We Energies selects Frictionless SRM Software
Post Your Comments:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
Breaking Biology News(10 mins):